Agena Bioscience today announced the appointment of David Coorey as Vice President and Managing Director, EMEA.
David joins Agena Bioscience from Becton Dickinson, where he most recently held the position of Business Unit Director for the Diagnostic Systems Division. David brings over 20 years’ experience leading strategy and commercialization across a range of medical device, genomics, and diagnostic companies such as Affymetrix, Gambro Healthcare, and Fresenius Kabi.
“We are delighted to have David lead our Europe, Middle East, and Africa organization,” said Pete Dansky, Chief Executive Officer of Agena Bioscience. “His distinguished track record in building and motivating growth in the EMEA life science and molecular diagnostics industries will help continue to drive Agena Bioscience’s strategy and commercial execution in EMEA.”
Agena Bioscience recently announced the launch of its CE-IVD marked MassARRAY® Dx products for sale in Europe, a genetic analysis system that enables reliable multiplexed analysis of up to hundreds of clinically relevant mutations in a single workflow.
“I’m excited by the potential of Agena Bioscience’s technology to enable better patient care in Europe through the unique combination of reliability, sensitivity, ease of use, and cost-effectiveness for targeted genetic testing,” said David Coorey.
The MassARRAY System and MassARRAY Dx enable mid-plex targeted profiling of 10’s to 100s of genetic markers. The technology offers a practical solution for today’s clinical and translational research labs with improvements in cost, throughput, reimbursement, and ease of use over alternative methods.